Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial

Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial

Abstract Purpose The combination of taxanes and anthracyclines is still the mainstay of chemotherapy for early breast cancer. Capecitabine is an active drug with a favorable toxicity profile, showing strong anti-tumor activity against metastatic breast cancer. This trial assessed the efficacy and sa...

Full description

Bibliographic Details
Main Authors: Houpu Yang, Ling Xu, Shan Guan, Xiaopeng Hao, Zhicheng Ge, Fuzhong Tong, Yingming Cao, Peng Liu, Bo Zhou, Lin Cheng, Miao Liu, Hongjun Liu, Fei Xie, Siyuan Wang, Yuan Peng, Chaobin Wang, Shu Wang
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Cancer
Subjects:
Breast neoplasms
Neoadjuvant therapy
Anthracycline
Taxane
Capecitabine
Online Access:https://doi.org/10.1186/s12885-022-10439-0

Internet

https://doi.org/10.1186/s12885-022-10439-0

Similar Items